BERGENBIO ASA Bergen, Norway ,28 September 2020 -BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, notes that following a rise in the number of COVID-19 cases in theUK ,UK Research and Innovation (UKRI) has decided to reinstate funding for the COVID-19 ACCORD clinical study in whichBerGenBio's bemcentinib is the lead drug candidate to be tested.The University Hospital Southampton NHS Trust remains the study sponsor, however the trial will be managed by the Medicines Evaluation Unit atManchester University . Three drug candidates will be evaluated in the trial, it is anticipated that up to 25 UK sites in the ACCORD study will recruit patients into the trial and that patient recruitment will recommence within weeks. The ACCORD study is a multicentre, seamless, Phase II adaptive randomisation platform trial to assess the efficacy and safety of multiple candidate agents, the first of which is bemcentinib, for the treatment of COVID-19 in hospitalisedUK NHS patients. Funding for the study was suspended by UKRI in July due to the falling number of hospitalised COVID-19 patients acrossUK trial sites.BerGenBio will make a modest financial contribution to the cost for the study and provide bemcentinib drug material. 60 hospitalised COVID-19 patients will receive bemcentinib and 60 patients in a control group will receive standard of care treatment. The trial protocol will permit enrolled patients with COVID-19, who meet the inclusion criteria for the study, to potentially receive bemcentinib plus one or both of the two recently recommended treatments for COVID-19: dexamethasone and remdesivir. Data will be open source and freely available to enable global knowledge sharing and collaboration. Data previously gathered before the cessation of the trial in July will be included in the analysis.BerGenBio has also received full regulatory and ethics clearance for its company sponsored Phase II trial (BGBC020) to assess the efficacy and safety of bemcentinib for the treatment of COVID-19 in hospitalised patients inSouth Africa and dosing is due to commence imminently. The Company is also in late stage set-up phase to expand the study to include additional hospital sites inIndia and expects to be in a position to update the market in the near future.Richard Godfrey , Chief Executive Officer ofBerGenBio , commented: "In recent weeks COVID-19 infection rates have unfortunately increased rapidly in theUK . With still no approved treatment or cure in place, and the hospitalised patient population now becoming large enough to support the trial, the decision has been taken to reinstate the ACCORD programme to continue investigating the potential of bemcentinib and two other agents as treatments for COVID19 patients. We believe bemcentinib has great promise and welcome the opportunity to recommence participation in theUK trial. We also look forward to continuing our own studies, using a similar protocol, inSouth Africa andIndia ." - END - About ACCORDThe ACcelerating COVID-19 Research & Development platform (ACCORD) study is being funded by theUK Research and Innovation (UKRI) with modest financial contribution byBerGenBio and the other drug candidate contributing companies, to rapidly test potential drugs through early stage clinical trials and feed them into theUK's large-scale COVID-19 studies such as the RECOVERY trial (https://www.nihr.ac.uk/urgent-public-health-research-studies-for-covid -19/randomised-evaluation-of-covid-19-therapy-recovery/24513), currently the world's largest randomised controlled clinical trial for COVID-19 treatment. About AXL AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying many life-threatening diseases. In cancer, AXL suppresses the body's immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases. About Bemcentinib Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers. AboutBerGenBio ASA BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in -class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel,BerGenBio is developing companion diagnostic tests to identify patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.BerGenBio is based inBergen, Norway with a subsidiary inOxford, UK . The company is listed on theOslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com About The Medicines Evaluation Unit (MEU) The Medicines Evaluation Unit (MEU) is a leading specialist clinical research facility working with the pharmaceutical industry to identify potential new treatments for respiratory disease and conditions such as Asthma, COPD, Cystic Fibrosis, Hypertension, Psoriasis. MEU has an outstanding reputation within the industry for performing high quality clinical research complying with strict clinical trial legislation. MEU has successfully conducted over 360 clinical trials. ContactsRichard Godfrey CEO,BerGenBio ASA +47 917 86 304Rune Skeie , CFO,BerGenBio ASA rune.skeie@bergenbio.com +47 917 86 513 International Media RelationsMary-Jane Elliott ,Chris Welsh ,Lucy Featherstone ,Carina Jurs Consilium Strategic Communications bergenbio@consilium-comms.com +44 20 3709 5700 Media Relations inNorway Jan Petter Stiff , Crux Advisers stiff@crux.no +47 995 13 891 Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source
